Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.
A trial looking at cabazitaxel for cancer of the penis that has come back after treatment (JAVA-P)
This trial looked at a chemotherapy drug called cabazitaxel to improve treatment for cancer of the penis. Cancer of the penis is also called penile cancer.
It was for men whose cancer had grown into surrounding tissue or had spread elsewhere in the body. This is locally advanced or advanced cancer.
This trial was open for people to join between 2014 and 2017, and the team published the results in 2019.
More about this trial
You might have chemotherapy for advanced cancer of the penis. But sometimes it can start to grow again. So doctors are looking for ways to improve treatment.
In this trial, researchers looked at a chemotherapy drug called cabazitaxel (Jevtana).
The main aims of the study were to find out:
- if cabazitaxel works for cancer of the penis that has come back
- more about the side effects
- more about quality of life
Summary of results
The trial team found that cabazitaxel did not work for cancer of the penis that had come back. But the side effects weren’t too bad.
About this trial
This was a phase 2 trial.
The researchers planned for 17 men to take part. They looked at the results after 9 men had joined. Of those:
- 7 had cancer that had spread elsewhere in the body
- 2 had cancer that had grown into surrounding tissues
Everyone had cabazitaxel. They had up to
The team checked the scans to see whose cancer had gone away completely or a little bit.
This had not happened in anyone so no more people joined the trial and it closed.
Quality of life
The team looked at how treatment affected
Most people had side effects that were mild.
3 people had more severe side effects. These included:
- a drop in the number of red blood cells (
- a drop in the number of
neutrophilswhich led to a serious infection (neutropenic sepsis)
- being sick
There were no treatment delays or dose reductions due to side effects.
The trial team concluded that cabazitaxel didn’t work for penile cancer that had come back. So the team closed the trial earlier than planned. They think it might be worth looking at cabazitaxel in combination with other drugs for cancer of the penis rather than having it as a treatment on its own.
All trial results help doctors and researchers understand more about different cancers and the best way to treat them.
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr Amit Bahl
NIHR Clinical Research Network: Cancer
University Hospitals Bristol NHS Foundation Trust